ACCOLADE, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.27 USD | -0.86% |
|
+6.21% | -23.06% |
| Apr. 22 | Stifel Adjusts Accolade's Price Target to $13 From $15, Keeps Buy Rating | MT |
| Mar. 19 | Accolade, Inc. Promotes Kelsi McDonald Harris to Chief People Officer and Senior Vice President | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 60% by 2026.
- The company is in a robust financial situation considering its net cash and margin position.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -23.06% | 724M | C- | ||
| -13.84% | 86.34B | B- | ||
| +17.58% | 84.49B | C+ | ||
| +10.92% | 29.68B | C+ | ||
| -8.75% | 17.5B | B | ||
| -2.67% | 16.67B | A- | ||
| -0.01% | 15.18B | A- | ||
| -3.63% | 12.71B | A- | ||
| +2.63% | 12.53B | A- | ||
| -30.53% | 11.89B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ACCD Stock
- Ratings Accolade, Inc.
